Chemours (CC) Q2 2026 earnings review
TSS Growth Engine Stalls, Masking a Stealth Guidance Cut
Chemours delivered a $247M Adjusted EBITDA beat in Q2, but the underlying narrative shifted negatively. The company's primary growth engine, Thermal & Specialized Solutions (TSS), stalled completely, reversing from a 22% surge in Q1 to a 1% decline in Q2 due to elevated aftermarket inventory. While Titanium Technologies (TT) finally stabilized with positive YoY growth, management executed a stealth cut to full-year EBITDA guidance, dropping the range to $775M-$825M from the prior $800M-$900M target. Furthermore, the balance sheet took another severe blow from legacy PFAS liabilities, resulting in a $274M GAAP net loss due to new EPA and WVDEP settlements.
🐂 Bull Case
TT volumes jumped 15% sequentially and prices rose 3%, marking an end to the prolonged destocking cycle and driving 18% sequential revenue growth.
Free cash flow surged 128% YoY to $114M. Combined with Kuan Yin land sale proceeds, this allowed the company to pay down €230M in debt and reduce net leverage to 4.4x.
🐻 Bear Case
The highly profitable refrigerant segment buckled under an inventory overhang. Revenue contracted 1% YoY, and Q3 is guided down up to 20% sequentially.
Management quietly lowered the FY26 Adjusted EBITDA target from the $800-900M range provided in Q1 to a new range of $775-825M, blaming H2 aftermarket weakness.
⚖️ Verdict: 🔴
Bearish. The sudden reversal of the TSS segment and the hidden guidance cut fundamentally weaken the near-term earnings outlook. While TT is recovering, the chronic nature of the environmental settlements continues to erode the equity story.
Key Themes
TSS Growth Hits a Wall
Reversing. After four quarters of exceptional double-digit expansion—peaking at 22% YoY in 26Q1—TSS revenue contracted 1% YoY in Q2. The regulatory tailwinds of the U.S. AIM Act have been temporarily neutralized by elevated channel inventory in the aftermarket. More worryingly, management expects this destocking to accelerate, guiding for a mid-teens to 20% sequential revenue drop in Q3. The company's primary growth engine has stalled.
A Stealth Cut to Annual Guidance
In the earnings release, management stated they 'continue to expect' FY26 Adjusted EBITDA between $775 million and $825 million. However, data directly contradicts this framing: in both Q4 2025 and Q1 2026, the official FY26 guidance was $800M - $900M. This is a material, unacknowledged downward revision that exposes significant second-half weakness.
Titanium Technologies Rebounding on Pricing
Accelerating. TT revenue grew 18% sequentially and flipped to positive YoY growth (+1%) for the first time in over a year. The recovery was balanced: global volumes jumped 15% and prices increased 3% sequentially, proving that recent global pricing actions are sticking as destocking ends. However, the macro picture remains mixed as inflation continues to weigh on the segment's cost base, keeping EBITDA margins suppressed at 7%.
APM AI Tailwinds Gaining Traction
Accelerating. While headline APM revenue fell 6% YoY due to the planned exit of the Capstone line, the underlying Performance Solutions portfolio is thriving. Sales in this sub-segment surged 42% sequentially and 8% YoY to $142M. This growth is heavily supported by a strong order book for high-value specialty products serving data center and semiconductor end markets, validating the strategic pivot toward AI-adjacent applications.
The Perpetual PFAS Drain
Stable/Ongoing. For the second consecutive Q2, Chemours posted a massive GAAP net loss due to legacy liabilities. Last year it was the New Jersey settlement (-$380M net loss); this year it is reserves for the EPA and WVDEP settlements (-$274M net loss). While management routinely excludes these from Adjusted EBITDA, they are a chronic cash and balance sheet drain, driving $394M in recognized litigation and environmental charges over the trailing twelve months.
Other KPIs
Reversing to positive. FCF more than doubled year-over-year, bouncing back from a $93 million outflow in Q1. Improved working capital execution allowed for a 46% FCF conversion rate. This liquidity was aggressively deployed to pay down €230 million of the B-3 Euro Term Loan, pushing the company closer to its 3.8x net leverage target.
Accelerating sequentially. Up 420% from a dismal $5 million in Q1, signaling the successful resolution of the Washington Works site outage that crippled the segment earlier in the year.
Guidance
Decelerating. This is a stealth downward revision from the $800 - $900 million range projected in Q1. The cut reflects a much weaker second-half outlook for the TSS segment due to aftermarket inventory overhang, which completely wipes out the Q2 earnings beat.
Decelerating. The midpoint of $190M implies a steep sequential decline from Q2's $247M and a slight YoY drop from Q3 2025's $195M, heavily pressured by the guided drop in TSS volumes.
Decelerating sharply. The anticipated drop is far worse than standard seasonality, as the market digests elevated inventory levels from the initial AIM Act channel fill in mid-2025.
Accelerating slightly. Demonstrates that the positive volume and pricing momentum captured in Q2 is expected to carry forward into the back half of the year.
Key Questions
Bridging the Guidance Cut
You stated in the release that you 'continue to expect' FY26 Adjusted EBITDA of $775M to $825M, but last quarter the guidance was $800M to $900M. Can you walk through the specific headwinds driving this downward revision and clarify if it is entirely attributable to TSS aftermarket weakness?
TSS Destocking Timeline
With TSS aftermarket demand softening significantly due to elevated channel inventory, how many quarters will this destocking phase last before we see a return to normalized AIM Act-driven growth?
TT Margin Compression
TT prices increased 3% sequentially and volumes surged 15%, yet the segment margin remained flat at 7%. How much of the pricing action is simply chasing ongoing cost inflation versus actual margin expansion, and when can we expect TT margins to return to double digits?
Unresolved Legacy Liabilities
With the EPA and WVDEP settlements booked this quarter, what major legacy PFAS liabilities remain unresolved across your operations, and what is the estimated timeline to move past these massive reserve additions?